Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis
NCT ID: NCT01223976
Last Updated: 2010-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
150 participants
INTERVENTIONAL
2010-11-30
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recently, a new assay for LTBI has been developed, which evaluates interferon (IFN) -γ release by memory effector T-cells stimulated in vitro with specific mycobacterial antigens, ESAT-6 (early secretory antigen target-6) and CFP-10 (culture filtrate protein-10) \[9-10\]. The QuantiFeron -TB Gold test (QFT-G) uses ELISA to measure IFN-γ concentrations in supernatants in plate format and "In tube" format (QFT-GIT) while the enzyme-linked immunospot (ELISPOT) detects individual IFN-γ producing T-cells (TS-TB, Oxford Immunotech, Abingdon, UK).
The whole blood IFN-γ assays was approved by The Centers for Disease Control as an alternative screening strategy to TST in immunocompetent individuals \[11\], but its clinical utility as a single test for detection LTBI in immunocompromised patients is controversial.Furthermore, its utility in patients with psoriasis and psoriatic arthritis has not been yet established One hundred patients with psoriasis and psoriatic arthritis and 50 healthy control will participate in this study.
Enrolled subjects will be requested to complete a detailed sociodemographic and TB screening questionnaire including gender, age, place of birth and work, prior BCG vaccination, close contact with TB patients or TB prophylaxis in the past. Screening workup will includ assessment of clinical disease activity using the Disease Activity Score 28 (DAS-28)and Psoriasis Area Severity Index (PASI),documentation of past or current treatment with systemic corticosteroids and immunosuppressive drugs, and imaging (chest X-ray).
All the subjects will undergo a TST and QFT-G test A 2-TU dose of PPD will be administered by a certified technician using the Mantoux method and induration measured after 72 h. TST will be deemed positive if bove or equally to 5 mm for RA patients and 10 mm for controls The absence of induration of \<2 mm in diameter will be recorded as anergic and negative TST results was defined as having more than 2 but less than 5 mm reactions for RA patients.
QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions.
Briefly, the test consisted of a negative control (nil well, i.e., whole blood without antigens or mitogen),a positive control (mitogen well, i.e., whole blood stimulated with the mitogen phytohemagglutinin \[PHA\]) and two sample wells, i.e., whole blood stimulated with either of the M. tuberculosis-specific antigens, Early Secretory Antigen Target 6 (ESAT-6) or Culture Filtrate Protein 10 (CFP-10).
Five ml heparinized whole blood will be drawn for QFT-G before for PPD testing. The blood specimens will be incubated for 16-20 h (overnight) at 37°C in a humidified atmosphere. IFN-γ levels in the nil well will be considered background and will be subtracted from the results of the mitogen well and the antigen-stimulated wells. The results will be considered positive if the concentration of.IFN-γ in the sample well after stimulation with ESAT-6 and/or CFP-10 will be greater than or equal to 0.35 IU/ml (after subtracting the value of the nil well), regardless of the results of the positive control (mitogen well). The results will be considered negative if the response to the specific antigens (after subtracting the value of the nil well) is less than 0.35 IU/ml and if the IFN-γ levels of the positive control (after subtracting the value of the nil well) is greater than or equal to 0.5 IU/ml. The results will be considered indeterminate if both antigen-stimulated sample wells are negative (i.e., \<0.35 IU/ml after subtracting the value of the Nil well) and if the value of the positive control well is less than 0.5 IU/ml after subtracting the value of the nil well
the nil well.
QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) was performed and interpreted according to the manufacturer's instructions.
Briefly, the test consisted of a negative control (nil well, i.e., whole blood without antigens or mitogen) , a positive control (mitogen well, i.e., whole blood stimulated with the mitogen phytohemagglutinin \[PHA\]) and two sample wells, i.e., whole blood stimulated with either of the M. tuberculosis-specific antigens, Early Secretory Antigen Target 6 (ESAT-6) or Culture Filtrate Protein 10 (CFP-10).
Five ml heparinized whole blood was drawn for QFT-G before for PPD testing. The blood specimens were incubated for 16-20 h (overnight) at 37°C in a humidified atmosphere. IFN-γ levels in the nil well were considered background and were subtracted from the results of the mitogen well and the antigen-stimulated wells. The results were considered positive if the concentration of. IFN-γ in the sample well after stimulation with ESAT-6 and/or CFP-10 was greater than or equal to 0.35 IU/ml (after subtracting the value of the nil well), regardless of the results of the positive control (mitogen well). The results were considered negative if the response to the specific antigens (after subtracting the value of the nil well) was less than 0.35 IU/ml and if the IFN-γ levels of the positive control (after subtracting the value of the nil well) were greater than or equal to 0.5 IU/ml. The results were considered indeterminate if both antigen-stimulated sample wells were negative (i.e., \<0.35 IU/ml after subtracting the value of the Nil well) and if the value of the positive control well was less than 0.5 IU/ml after subtracting the value of
the nil well.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tuberculin skin test and Quantiferon -TB Gold test
TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.
QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-90
Exclusion Criteria
* Known allergy to TST
* Current or past treatment with anti-TNF alpha
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tel Aviv Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tel Aviv Medical Center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chiang YZ, Panting K, Dever B, Parslew RA. Clinical applicability of T-cell interferon-a release assay for tumour necrosis factor-a inhibitor therapy in severe psoriasis. Clin Exp Dermatol. 2011 Jan;36(1):39-41. doi: 10.1111/j.1365-2230.2010.03850.x.
Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, Panizzon RG, Saurat JH. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol. 2009 Oct;161(4):797-800. doi: 10.1111/j.1365-2133.2009.09331.x. Epub 2009 Jun 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
222-10
Identifier Type: -
Identifier Source: org_study_id